SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy

Thisi is an Interventional drug-free randomized 1:1 open-label, multicenter, phase 3 trial in patients with first-line metastatic pancreatic cancer. The interventional group of patients will undergo radiotherapy on the primary lesion and SBRT on distal metastatic sites before receiving standard systemic therapy (chemotherapy), while the other group of patients will receive only standard systemic therapy (chemotherapy) without undergoing radiotherapy.

NCT Number	NCT06946420
Lead Sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions	Radiation Therapy, SBRT, Pancreatic Cancer Metastatic
Enrollment	108 participants
Start Date	2025-01-10
Primary Completion	2030-01-10 (estimated)
Study Completion	2031-01-10 (estimated)
Updated on ClinicalTrials.gov	2025-04-27